Jóri, B.; Vössing, C.; Pirngruber, J.; Willing, E.M.; Arndt, K.; Falk, M.; Tiemann, M.; Heukamp, L.C.; Hoffknecht, P.
The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations. Curr. Oncol. 2023, 30, 8805-8814.
https://doi.org/10.3390/curroncol30100635
AMA Style
Jóri B, Vössing C, Pirngruber J, Willing EM, Arndt K, Falk M, Tiemann M, Heukamp LC, Hoffknecht P.
The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations. Current Oncology. 2023; 30(10):8805-8814.
https://doi.org/10.3390/curroncol30100635
Chicago/Turabian Style
Jóri, Balázs, Christine Vössing, Judith Pirngruber, Eva Maria Willing, Kathrin Arndt, Markus Falk, Markus Tiemann, Lukas C. Heukamp, and Petra Hoffknecht.
2023. "The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations" Current Oncology 30, no. 10: 8805-8814.
https://doi.org/10.3390/curroncol30100635
APA Style
Jóri, B., Vössing, C., Pirngruber, J., Willing, E. M., Arndt, K., Falk, M., Tiemann, M., Heukamp, L. C., & Hoffknecht, P.
(2023). The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations. Current Oncology, 30(10), 8805-8814.
https://doi.org/10.3390/curroncol30100635
